Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again
As some analysts had fretted about, the FDA was unable to schedule an inspection of one of the manufacturing sites that was to be used for the production of liso-cel, their CAR-T picked up in the buyout, which was originally developed by Juno. As a result, Bristol Myers reported today that the FDA will not meet its PDUFA date today.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.